Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) in the real-world setting

Ann Oncol. 2019 Jan 1;30(1):151-152. doi: 10.1093/annonc/mdy482.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Humans
  • Lymphoma, Large B-Cell, Diffuse*
  • Progression-Free Survival*
  • Randomized Controlled Trials as Topic
  • Rituximab

Substances

  • Rituximab